Skip to main content
Ophthalmic Surgery, Lasers and Imaging Retina, 2014;45(6):521–524
Published Online:https://doi.org/10.3928/23258160-20141118-06Cited by:19

Abstract

BACKGROUND AND OBJECTIVE:

To compare intravitreal bevacizumab versus ranibizumab as adjuvant treatment prior to pars plana vitrectomy (PPV) in proliferative diabetic retinopathy (PDR) with respect to parameters of surgical complexity.

PATIENTS AND METHODS:

Prospective, randomized, double-masked pilot study of patients requiring PPV for nonclearing vitreous hemorrhage or tractional retinal detachment (TRD) secondary to PDR. Patients were randomized to receive either intravitreal bevacizumab or ranibizumab at standard doses 1 week preoperatively. Measured parameters included total surgical time, presence of TRD, intraoperative bleeding, iatrogenic retinal breaks, and use of endolaser and endodiathermy or silicone oil.

RESULTS:

A total of 29 patients were recruited. For surgical parameters, there were no statistically significant differences between the groups in the univariate analyses. Multivariable analysis showed no statistically significant difference for total surgical time.

CONCLUSION:

This pilot study suggests that intravitreal bevacizumab and ranibizumab are equivalent as surgical adjuvants when used as pre-treatment in patients with PDR undergoing PPV.

[Ophthalmic Surg Lasers Imaging Retina. 2014;45:521–524.]

  • 1.Moss SE, Klein R, Klein BE. The 14-year incidence of visual loss in a diabetic population. Ophthalmology. 1998; 105(6):998–1003.

    > Crossref MedlineGoogle Scholar
  • 2.Fong , Ferris FL, Davis MD, Chew EY. Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no. 24. Am J Ophthalmol. 1999; 127(2):137–141.

    > Crossref MedlineGoogle Scholar
  • 3.[No authors listed]. Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Four-year results of a randomized trial: Diabetic retinopathy vitrectomy study report 5. Arch Ophthalmol. 1990; 108(7):958–964.

    > Crossref MedlineGoogle Scholar
  • 4.Chen E, Park CH. Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina. 2006; 26(6):699–700.

    > Crossref MedlineGoogle Scholar
  • 5.Zhao LQ, Zhu H, Zhao PQ, Hu YQ. A systematic review and meta-analysis of clinical outcomes of vitrectomy with or without intravitreal bevacizumab pretreatment for severe diabetic retinopathy. Br J Ophthalmol. 2011; 95(9):1216–1222.

    > Crossref MedlineGoogle Scholar
  • 6.Zhang ZH, Liu HY, Hernandez-Da Mota SE, et al.Vitrectomy with or without preoperative intravitreal bevacizumab for proliferative diabetic retinopathy: A meta-analysis of randomized controlled trials. Am J Ophthalmol. 2013; 156(1):106–115.

    > Crossref MedlineGoogle Scholar
  • 7.Rizzo S, Genovesi-Ebert F, Di Bartolo E, Vento A, Miniaci S, Williams G. Injection of intravitreal bevacizumab (avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). Graefes Arch Clin Exp Ophthalmol. 2008; 246(6):837–842.

    > Crossref MedlineGoogle Scholar
  • 8.Yeoh J, Williams C, Allen P, et al.Avastin as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy: A prospective case series. Clin Experiment Ophthalmol. 2008; 36(5):449–454.

    > MedlineGoogle Scholar
  • 9.Hernandez-Da Mota SE, Nunez-Solorio SM. Experience with intravitreal bevacizumab as a preoperative adjunct in 23-G vitrectomy for advanced proliferative diabetic retinopathy. Eur J Ophthalmol. 2010; 20(6):1047–1052.

    > Crossref MedlineGoogle Scholar
  • 10.Yeh PT, Yang CM, Lin YC, Chen MS, Yang CH. Bevacizumab pretreatment in vitrectomy with silicone oil for severe diabetic retinopathy. Retina. 2009; 29(6):768–774.

    > Crossref MedlineGoogle Scholar
  • 11.Ushida H, Kachi S, Asami T, Ishikawa K, Kondo M, Terasaki H. Influence of preoperative intravitreal bevacizumab on visual function in eyes with proliferative diabetic retinopathy. Ophthalmic Res. 2013; 49(1):30–36.

    > Crossref MedlineGoogle Scholar
  • 12.Modarres M, Nazari H, Falavarjani KG, Naseripour M, Hashemi M, Parvaresh MM. Intravitreal injection of bevacizumab before vitrectomy for proliferative diabetic retinopathy. Eur J Ophthalmol. 2009; 19(5):848–852.

    > Crossref MedlineGoogle Scholar
  • 13.di Lauro R, De Ruggiero P, di Lauro R, di Lauro MT, Romano MR. Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2010; 248(6):785–791.

    > Crossref MedlineGoogle Scholar
  • 14.Gupta A, Bansal R, Gupta V, Dogra MR. Six-month visual outcome after pars plana vitrectomy in proliferative diabetic retinopathy with or without a single preoperative injection of intravitreal bevacizumab. Int Ophthalmol. 2012; 32(2):135–144.

    > Crossref MedlineGoogle Scholar
  • 15.Rosenfeld PJ, Brown DM, Heier JS, et al.Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006; 355(14):1419–1431.

    > Crossref MedlineGoogle Scholar
  • 16.Brown DM, Kaiser PK, Michels M, et al.Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006; 355(14):1432–1444.

    > Crossref MedlineGoogle Scholar
  • 17.Iturralde D, Spaide RF, Meyerle CB, et al.Intravitreal bevacizumab (avastin) treatment of macular edema in central retinal vein occlusion: A short-term study. Retina. 2006; 26(3):279–284.

    > Crossref MedlineGoogle Scholar
  • 18.Rabena MD, Pieramici DJ, Castellarin AA, Nasir MA, Avery RL. Intravitreal bevacizumab (avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina. 2007; 27(4):419–425.

    > Crossref MedlineGoogle Scholar
  • 19.Brown DM, Nguyen QD, Marcus DM, et al.Long-term outcomes of ranibizumab therapy for diabetic macular edema: The 36-month results from two phase III trials: RISE and RIDE. Ophthalmology. 2013; 120(10):2013–2022.

    > Crossref MedlineGoogle Scholar
  • 20.Mitchell P, Bandello F, Schmidt-Erfurth U, et al.The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011; 118(4):615–625.

    > Crossref MedlineGoogle Scholar
  • 21.Laud K, Spaide RF, Freund KB, Slakter J, Klancnik JM. Treatment of choroidal neovascularization in pathologic myopia with intravitreal bevacizumab. Retina. 2006; 26(8):960–963.

    > Crossref MedlineGoogle Scholar
  • 22.Nguyen QD, Shah S, Tatlipinar S, Do DV, Anden EV, Campochiaro PA. Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia. Br J Ophthalmol. 2005; 89(10):1368–1370.

    > MedlineGoogle Scholar
  • 23.Ma Y, Zhang Y, Zhao T, Jiang YR. Vascular endothelial growth factor in plasma and vitreous fluid of patients with proliferative diabetic retinopathy patients after intravitreal injection of bevacizumab. Am J Ophthalmol. 2012; 153(2):307–313.

    > Crossref MedlineGoogle Scholar
  • 24.Hattori T, Shimada H, Nakashizuka H, Mizutani Y, Mori R, Yuzawa M. Dose of intravitreal bevacizumab (avastin) used as preoperative adjunct therapy for proliferative diabetic retinopathy. Retina. 2010; 30(5):761–764.

    > Crossref MedlineGoogle Scholar
  • 25.El-Sabagh HA, Abdelghaffar W, Labib AM, et al.Preoperative intravitreal bevacizumab use as an adjuvant to diabetic vitrectomy: Histopathologic findings and clinical implications. Ophthalmology. 2011; 118(4):636–641.

    > Crossref MedlineGoogle Scholar
  • 26.Papadopoulos N, Martin J, Ruan Q, et al.Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012; 15(2):171–185.

    > Crossref MedlineGoogle Scholar
  • 27.Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 2007; 114(5):855–859.

    > Crossref MedlineGoogle Scholar
  • 28.Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology. 2007; 114(12):2179–2182.

    > Crossref MedlineGoogle Scholar
  • 29.Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004; 3(5):391–400.

    > Crossref MedlineGoogle Scholar
  • 30.Christoforidis JB, Williams MM, Wang J, et al.Anatomic and pharmacokinetic properties of intravitreal bevacizumab and ranibizumab after vitrectomy and lensectomy. Retina. 2013; 33(5):946–952.

    > Crossref MedlineGoogle Scholar
  • 31.CATT Research GroupMartin DF, Maguire MG, et al.Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011; 364(20):1897–1908.

    > Crossref MedlineGoogle Scholar
  • 32.Chakravarthy U, Harding SP, Rogers CA, et al.Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet. 2013; 382(9900):1258–1267.

    > Crossref MedlineGoogle Scholar
  • 33.Kodjikian L, Souied EH, Mimoun G, et al.Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: Results from the GEFAL noninferiority randomized trial. Ophthalmology. 2013; 120(11):2300–2309.

    > Crossref MedlineGoogle Scholar

We use cookies on this site to enhance your user experience. For a complete overview of all the cookies used, please see our privacy policy.

×